CN109776656A - It is a kind of for the peptide T IN7N of angiogenesis inhibiting and its application - Google Patents
It is a kind of for the peptide T IN7N of angiogenesis inhibiting and its application Download PDFInfo
- Publication number
- CN109776656A CN109776656A CN201910030074.2A CN201910030074A CN109776656A CN 109776656 A CN109776656 A CN 109776656A CN 201910030074 A CN201910030074 A CN 201910030074A CN 109776656 A CN109776656 A CN 109776656A
- Authority
- CN
- China
- Prior art keywords
- peptide
- in7n
- disease
- angiogenesis
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 47
- 108010071384 Peptide T Proteins 0.000 title claims abstract description 35
- 230000002401 inhibitory effect Effects 0.000 title abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 208000030533 eye disease Diseases 0.000 claims description 9
- 208000027129 choroid disease Diseases 0.000 claims description 8
- 230000002207 retinal effect Effects 0.000 claims description 8
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 208000023343 iris disease Diseases 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 208000021921 corneal disease Diseases 0.000 claims description 4
- 208000013649 vitreous body disease Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
- 208000021328 arterial occlusion Diseases 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 210000001525 retina Anatomy 0.000 claims description 3
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 150000003891 oxalate salts Chemical class 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 208000011581 secondary neoplasm Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- -1 hydrobromate Chemical class 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000001647 drug administration Methods 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 241000252212 Danio rerio Species 0.000 description 24
- 230000002792 vascular Effects 0.000 description 15
- 229960000397 bevacizumab Drugs 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000000049 pigment Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 206010064930 age-related macular degeneration Diseases 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000005081 epithelial layer Anatomy 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000003606 umbilical vein Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- SQZIAWGBBUSSPJ-ZKWXMUAHSA-N Asn-Cys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N SQZIAWGBBUSSPJ-ZKWXMUAHSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 101100227322 Caenorhabditis elegans fli-1 gene Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- QSVCIFZPGLOZGH-WDSKDSINSA-N Gly-Glu-Ser Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QSVCIFZPGLOZGH-WDSKDSINSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- 101100281205 Mus musculus Fli1 gene Proteins 0.000 description 1
- RAGOJJCBGXARPO-XVSYOHENSA-N Phe-Thr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 RAGOJJCBGXARPO-XVSYOHENSA-N 0.000 description 1
- VFWQQZMRKFOGLE-ZLUOBGJFSA-N Ser-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O VFWQQZMRKFOGLE-ZLUOBGJFSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 1
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005157 neural retina Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of peptide T IN7N, amino acid sequence is the amino acid sequence compared with SEQ ID NO.1 with 13/16 or more sequence identity；And the purposes in the drug of peptide T IN7N or its pharmaceutically acceptable salt disease caused by preparation treatment and/or prevention angiogenesis；The invention also discloses a kind of for treating the pharmaceutical composition of disease caused by angiogenesis, and it includes the salt that peptide T IN7N or peptide T IN7N pharmaceutically receive, and the carrier pharmaceutically received.Compared with the drug of existing angiogenesis inhibiting, 16 amino acid of (1) peptide T IN7N long are had the advantage that, have and be readily synthesized, be low in cost；(2) peptide T IN7N has the function of significant angiogenesis inhibiting；(3) dissolubility of peptide T IN7N in water is preferable, is easy to pass through drug administration by injection.
Description
Technical field
The present invention relates to biomedicine technical field, especially a kind of peptide T IN7N for angiogenesis inhibiting and its
Using.
Background technique
Angiogenesis (angiogenesis) refers to the formation, development and growth of new vessels.In general, angiogenesis
By stringent regulation, mainly by induction of vascular formed the factor (such as vascular endothelial growth factor VEGF) and inhibition because
Delicate balance between son regulates and controls.When this equilibrium state is broken, it will usually cause pathological.Angiogenesis
It is dynamic, multi-step a process, it is now known that a variety of diseases are related to angiogenesis disorder, such as cancer, ocular angiogenesis
Abnormal, infection, cardiovascular disease and damage etc., therefore study angiogenesis inhibitors and be of great significance.The master of angiogenesis
Wanting process includes blood vessel basement membrane degradation, activation, proliferation, the migration of vascular endothelial cell, in original blood vessel base in such a way that bud is raw
New blood vessel and rete vasculosum are reconstructed on plinth, this process mainly generates stimulating factor induction, such as VEGF by soluble vascular.
The formation of new capillary vessel is the key point of many disease development and diffusion, including tumour, diseases associated with inflammation
With some eye syndromes.Neovascular eye diseases are ophthalmology refractory diseases, and the major reason of many eye disease blindings, example
Such as neovascular disease of cornea, retinal disease, Iris diseases, choroidal diseases or vitreous body disease and eye traumas.Year
Age macular degeneration related (age-related macular degeneration, AMD) is a kind of age-related, view
Irreversibility visual impairment caused by membranochromic pigments epithelial cell and neural retina retrogression or the disease of forfeiture.The whole world there are about
30000000 AMD patients, there are about 500,000 people therefore blindings every year.As China's economic development and the aggravation of aging of population, AMD exist
China's disease incidence shows an increasing trend year by year, and there is ten thousand AMD patient more than 500 in China, it has also become the third-largest causes of blindness in China.AMD
It is central area retina Chronic Progressive disease, is clinically broadly divided into atrophic type (stemness) and exudative type (moist) two major classes:
Atrophic type AMD often shows as the decline of binocular vision progressive, it is seen that macular area pigment disorder, choroidal capillaries atrophy and glass
The formation of glass film wart.Exudative type be mainly characterized by choroidal neovascularization (choroidal neovascularization,
A series of pathological changes such as formation CNV) and caused exudation, bleeding, machine, scar.10% AMD is new green blood
Pipe leakage type (i.e. moist), but blindness caused by it accounts for 90%.In recent years, for the basis of angiogenesis and clinical research
Greater advance is achieved, in neovascular disease of cornea, retinal disease, Iris diseases, choroidal diseases or vitreum
The new vessels such as disease and eye traumas generate in diseases related, are formed by reducing new vessels, can achieve control disease
Development, the effect for improving clinical symptoms.
The growth of tumour and transfer depend on angiogenesis, angiogenesis be growth of tumour cell, proliferation, transfer can not or
One of scarce essential condition.In the case where no angiogenesis, tumor cell mass is filled by diffusion way from ambient enviroment
The nutrition of foot and oxygen, but gross tumor volume rarely exceeds 1mm at this time3~2mm3.1971, Folkman was put forward for the first time " tumour life
Long and transfer is blood vessel dependence, and blocking Tumor Angiongesis is the available strategy for checking tumour growth ", in this theoretical basis
The research of upper progress makes anti-angiogenic medicaments enter clinic, and good therapeutic effect is obtained in terms of oncotherapy.
The therapeutic targets of relevant diseases of angiogenesis are mainly VEGF at present, and common therapeutic agent is mainly that anti-vegf is anti-
Body (such as bevacizumab) or fusion protein, chemotherapeutics etc..But these drug prices are expensive, in field of medicaments for novel
Anti-angiogenic drugs still have larger demand.Polypeptide is the very potential a kind of candidate of field of biological pharmacy,
Have many advantages, such as that structure is simple, immunogenicity is low, is readily synthesized, is low in cost.Therefore, the polypeptide for being able to suppress angiogenesis exists
Treating cancer, ocular angiogenesis exception, infection, cardiovascular disease and damage etc. are with a wide range of applications.
Summary of the invention
Based on the above issues, providing one kind it is an object of the invention to overcome in place of above-mentioned the deficiencies in the prior art can
The polypeptide of angiogenesis inhibiting can be used for treating disease related with angiogenesis.
To achieve the above object, the technical solution that the present invention takes includes the following aspects:
In the first aspect, the present invention provides a kind of peptide T IN7N, the amino acid sequence of the peptide T IN7N be with
SEQ ID NO.1 compares the amino acid sequence with 13/16 or more sequence identity.Preferably, the amino of the peptide T IN7N
Acid sequence is the amino acid sequence compared with SEQ ID NO.1 with 14/16 or 15/16 sequence identity.It should be noted that
The amino acid sequence of peptide T IN7N of the invention includes but is not limited to have 13/16 or more sequence one compared with SEQ ID NO.1
The amino acid sequence of cause property can also be the amino acid sequence compared with SEQ ID NO.1 with 9/16~12/16 sequence identity
Column, as long as the polypeptide has the function of angiogenesis inhibiting, all fall in protection scope of the present invention.
Preferably, the amino acid sequence of the peptide T IN7N is as shown in SEQ ID NO.1.
In the second aspect, the present invention provides above-mentioned peptide T IN7N or its pharmaceutically acceptable salt controls in preparation
Purposes in the drug of disease caused by treatment and/or prevention angiogenesis.
Preferably, the salt is acetate, hydrochloride, hydrobromate, sulfate, phosphate, nitrate, oxalates or wine
Stone hydrochlorate.It is highly preferred that the salt is acetate.
Preferably, disease caused by the angiogenesis is eye disease or tumour.
Preferably, the eye disease be neovascular disease of cornea, retinal disease, Iris diseases, choroidal diseases or
Vitreous body disease.It is highly preferred that the retinal disease is diabetic retinopathy, retinal vein occlusion, premature
Retinopathy or retinal arterial obstruction.It is highly preferred that the choroidal diseases are wet age-related macular lesions.
Preferably, the tumour is primary tumor or secondary tumors.
In the third aspect, the present invention provides a kind of for treating the pharmaceutical composition of disease caused by angiogenesis,
Described pharmaceutical composition includes the salt that above-mentioned peptide T IN7N or the peptide T IN7N pharmaceutically receive, and pharmaceutically
The carrier of receiving.It should be noted that disease caused by angiogenesis is eye disease or tumour；Preferably, the eye disease is new life
Vascular disease of cornea, retinal disease, Iris diseases, choroidal diseases or vitreous body disease；It is highly preferred that the retina
Disease is diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity or retinal arterial obstruction；It is more excellent
Selection of land, the choroidal diseases are wet age-related macular lesions；Preferably, the tumour is primary tumor or secondary swollen
Tumor.
Preferably, the carrier is water or colloidal solution.
Preferably, the colloidal solution is hyaluronic acid derivatives.
Preferably, described pharmaceutical composition is to pass through drug administration by injection；It is highly preferred that the drug administration by injection includes vitreum note
It penetrates, be subcutaneously injected or be injected intravenously.
Compared with the drug of existing angiogenesis inhibiting, peptide T IN7N of the invention is had the advantage that
(1) 16 amino acid of peptide T IN7N long have and are readily synthesized, are low in cost；
(2) in cells in vitro experiment, peptide T IN7N can inhibit the blood of Human umbilical vein endothelial cells (HUVEC cell)
Pipe is formed and migration, and in zebra fish model of angiogenesis, peptide T IN7N can inhibit the formation of ocular angiogenesis, therefore,
Peptide T IN7N of the invention has the function of significant angiogenesis inhibiting；
(3) dissolubility of peptide T IN7N in water is preferable, is easy to pass through drug administration by injection.
Detailed description of the invention
Fig. 1 is PBS, TIN7N (100 μ g/ml), bevacizumab (100 μ g/ml) inhibits people HUVEC cellular vascular to be formed
Microscope photo；
Fig. 2 is PBS, TIN7N, bevacizumab inhibition people HUVEC cellular vascular forms the column diagram of result；
Fig. 3 is PBS, TIN7N (100 μ g/ml), bevacizumab (100 μ g/ml) inhibits the Transwell of people HUVEC cell
Photo；
Fig. 4 is PBS, TIN7N, bevacizumab inhibits the Transwell column diagram of people HUVEC cell；
Fig. 5 is physiological saline, TIN7N (1ng/ tail), bevacizumab (250ng/ tail) processing zebra fish ocular vascular proliferation
The ocular angiogenesis photo of model；
Fig. 6 is the ocular angiogenesis area of physiological saline, TIN7N, bevacizumab processing zebra fish ocular vascular proliferation model
Statistical results chart；
Fig. 7 is the pathological picture of physiological saline, TIN7N, bevacizumab processing zebra fish ocular vascular proliferation model.
Specific embodiment
To better illustrate the object, technical solutions and advantages of the present invention, below in conjunction with the drawings and specific embodiments pair
The present invention is described further.It should be pointed out that it will be apparent to those skilled in the art that before not departing from present inventive concept
It puts, many changes and improvements can be made, these are all within the scope of protection of the present invention.Unless otherwise instructed, in the application
Experimental method be conventional method.Unless otherwise instructed, the reagent concentration in the application is mass concentration.
The synthesis of 1 peptide T IN7N of embodiment
Peptide T IN7N (SEQ ID NO:1) is synthesized using conventional solid technique, the peptide purity > 98% of synthesis.
2 Human umbilical vein endothelial cells of embodiment (HUVEC cell) vascularization
Originally culture Human umbilical vein endothelial cells (HUVEC, Human umbilical vein endothelial
Cells), the TIN7N processing of 3 μ g/ml, 10 μ g/ml, 30 μ g/ml, 100 μ g/ml, 300 μ g/ml and 1000 μ g/ml, training is added
It supports after Matrigel matrigel, 4~6 hours, observe vascularization situation and counts, using PBS as negative control, 100 μ g/
Ml bevacizumab is as positive control.
As a result as illustrated in fig. 1 and 2, as can be seen from Figure, compared with negative control PBS, blood vessel of the TIN7N to HUVEC
Formation significantly inhibits (*: p < 0.05；*: p < 0.01), and dose-effect relationship is significant.
3 Transwell of embodiment detects cell migration ability
The cell for collecting the different pharmaceutical processing in embodiment 2, counts 1 × 105A cell, with free serum culture base weight
It is outstanding, the cell upper chamber of Transwell tissue culture plate is added, 600 μ l complete mediums are added in lower room.In 37 DEG C, 5%
CO2After being incubated for 12~48 hours under environment, cell is taken out, the cell of upper chamber is wiped with cotton swab, 4% paraformaldehyde is fixed
20mins, PBS washed once, violet staining 10mins, and PBS washed once, and whether microscopically observation cell passes through aperture,
Other experimental groups are terminated if any passing through, and statistics of taking pictures.
TIN7N can the dose-dependent migration (* *: p < 0.01) for inhibiting HUVEC it can be seen from Fig. 3,4.
Effect of the embodiment 4 to zebra fish ocular vascular proliferation model
The Fli-1 lines transgenic blood vessel fluorescence zebra fish that after fertilization 1 day (1dpf) is handled using cobalt chloride hexahydrate, is built
Vertical zebra fish ocular vascular proliferation model.Ocular vascular proliferation model zebra fish is randomly divided into 11 groups, and every group of 30 tails are in six orifice plates
In, dispensing, which is penetrated, gives TIN7N (dosage 1,3,10 and 30ng/ tail dosage), positive control bevacizumab 250ng/ tail, sets simultaneously
Set Normal group (normal zebra fish, injecting normal saline) and model control group (injecting normal saline).28 DEG C of incubators are incubated
After educating 5 days, every group takes 10 zebra fish at random, in fluorescence microscopy microscopic observation zebra fish ocular angiogenesis, takes pictures and saves picture.
Image analysis is carried out with high vision processing software Nikon NIS-Elements D 3.10, calculates zebra fish ocular angiogenesis area
(S), zebra fish ocular vascular proliferation that TIN7N induces cobalt chloride is evaluated respectively with the statistical significance of ocular angiogenesis area
Inhibiting effect.Statistical procedures result is indicated with mean ± SE, to the inhibiting effect calculation formula of zebra fish ocular vascular proliferation
It is as follows:
Statistical analysis is examined using variance analysis and Dunnett ' s T- and carries out statistical analysis, and p < 0.05 shows have
Significant difference.
Every test group separately takes 10 zebra fish, and ocular tissue is taken to be fixed with 4% paraformaldehyde, by dehydration, embeds, cuts
Piece and dyeing obtain H&E stained slice, carry out histopathological examination.
Fluirescence observation result is as shown in Figure 5 and Figure 6, and in positive control bevacizumab group, zebra fish ocular angiogenesis area is bright
Aobvious to be less than model control group ocular angiogenesis area (p < 0.001), the inhibiting effect to ocular vascular proliferation is 94%, shows that shellfish is cut down
Monoclonal antibody significantly inhibits zebra fish ocular vascular proliferation.Dosage is the TIN7N of 1,3,10 and 30ng/ tail to eye
Blood vessel hyperplasia inhibiting effect is respectively 91%, 48%, 58% and 57%, with the poor different equal highly significant of model control group (p <
0.001).The above result shows that TIN7N is to zebra fish eye in the case where being far below bevacizumab concentration (250ng/ tail)
Blood vessel hyperplasia has significant inhibiting effect.
Pathological examination as shown in fig. 7, the visible pigment epithelial layer of model control group zebra fish ocular tissue pathological examination compared with
Normal group is thinning, and three layers of pigment epithelial layer, visual sense cone layer and outer nuclear layer retinal structure are fuzzy, disorder, shows model
It is successfully established.Positive control drug bevacizumab group zebra fish ocular tissue pathological examination is showing pigment epithelial layer caliper recovery just
Often, pigment epithelial layer, visual sense cone layer and three layers of retinal structure of outer nuclear layer are clear, show bevacizumab to ocular vascular proliferation
Zebra fish retinal structure be significantly improved.Dosage is the TIN7N zebra fish ocular tissue pathological examination of 1ng/ tail
Show that pigment epithelial layer caliper recovery is normal, pigment epithelial layer, visual sense cone layer and three layers of retinal structure of outer nuclear layer are clear, agent
Amount is that the TIN7N zebra fish ocular tissue pathological examination of 3 and 10ng/ tail shows pigment epithelial layer thickness and pigment epithelium
Three layers of layer, visual sense cone layer and outer nuclear layer retinal structure are restored compared with model control group, show TIN7N to impaired view
Nethike embrane improves significantly.
By the result of above-described embodiment it is found that peptide T IN7N provided by the present invention can inhibit HUVEC cell in vitro
Vascularization and migration, the formation of ocular angiogenesis, therefore, polypeptide can be inhibited in zebra fish model of angiogenesis
TIN7N has the function of significant angiogenesis inhibiting, can be used for treating relevant diseases of angiogenesis, such as eye disease or tumour
Deng with obviously clinical value.
Finally it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than protects to the present invention
The limitation of range, although the invention is described in detail with reference to the preferred embodiments, those skilled in the art should be managed
Solution, can with modification or equivalent replacement of the technical solution of the present invention are made, without departing from technical solution of the present invention essence and
Range.
SEQUENCE LISTING
<110>Guangzhou Ling Sheng medical science and technology Co., Ltd
<120>a kind of for the peptide T IN7N of angiogenesis inhibiting and its application
<130> 2019
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 16
<212> PRT
<213>artificial sequence
<400> 1
Gly Glu Ser Leu Thr Ile Asn Cys Val Phe Thr Asp Ser Ser Cys Gly
1 5 10 15
Claims (13)
1. a kind of peptide T IN7N, which is characterized in that the amino acid sequence of the peptide T IN7N is that have compared with SEQ ID NO.1
There is the amino acid sequence of 13/16 or more sequence identity.
2. peptide T IN7N according to claim 1, which is characterized in that the amino acid sequence such as SEQ of the peptide T IN7N
Shown in ID NO.1.
3. peptide T IN7N described in claim 1 or its pharmaceutically acceptable salt are in preparation treatment and/or prevention angiogenesis
Purposes in the drug of caused disease.
4. purposes according to claim 3, which is characterized in that the salt is acetate, hydrochloride, hydrobromate, sulfuric acid
Salt, phosphate, nitrate, oxalates or tartrate.
5. purposes according to claim 3, which is characterized in that the salt is acetate.
6. purposes according to claim 3, which is characterized in that disease caused by the angiogenesis is eye disease or tumour.
7. purposes according to claim 6, which is characterized in that the eye disease is neovascular disease of cornea, retina
Disease, Iris diseases, choroidal diseases or vitreous body disease.
8. purposes according to claim 7, which is characterized in that the retinal disease be diabetic retinopathy,
Retinal vein occlusion, retinopathy of prematurity or retinal arterial obstruction.
9. purposes according to claim 7, which is characterized in that the choroidal diseases are wet age-related macular lesions.
10. purposes according to claim 6, which is characterized in that the tumour is primary tumor or secondary tumors.
11. a kind of for treating the pharmaceutical composition of disease caused by angiogenesis, which is characterized in that described pharmaceutical composition packet
The salt that peptide T IN7N of any of claims 1 or 2 or the peptide T IN7N pharmaceutically receive is included, and is pharmaceutically received
Carrier.
12. pharmaceutical composition according to claim 11, which is characterized in that the carrier is water or colloidal solution.
13. pharmaceutical composition according to claim 12, which is characterized in that the colloidal solution is hyaluronic acid derivatives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910030074.2A CN109776656B (en) | 2019-01-11 | 2019-01-11 | Polypeptide TIN7N for inhibiting angiogenesis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910030074.2A CN109776656B (en) | 2019-01-11 | 2019-01-11 | Polypeptide TIN7N for inhibiting angiogenesis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109776656A true CN109776656A (en) | 2019-05-21 |
| CN109776656B CN109776656B (en) | 2022-03-11 |
Family
ID=66500433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910030074.2A Active CN109776656B (en) | 2019-01-11 | 2019-01-11 | Polypeptide TIN7N for inhibiting angiogenesis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109776656B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ515388A (en) * | 1999-05-14 | 2003-03-28 | Genesis Res & Dev Corp Ltd | Polynucleotides and polypeptides used to stimulate leukocyte growth and to modulate angiogenesis and treat neurological conditions |
| CN102365093A (en) * | 2009-03-30 | 2012-02-29 | 参天制药株式会社 | Prophylactic or therapeutic agent for retinal diseases and method for preventing or treating retinal diseases, each comprising jnk (c-jun n-terminal kinase)-inhibiting peptide, and use of the peptide |
| WO2016115732A1 (en) * | 2015-01-23 | 2016-07-28 | 上海市第一人民医院 | Polypeptide for inhibiting angiogenesis or growth and application thereof |
| CN105859833A (en) * | 2015-01-23 | 2016-08-17 | 上海市第人民医院 | Polypeptide for inhibition of blood vessel neogenesis or growth and application thereof |
| CN106220714A (en) * | 2016-09-26 | 2016-12-14 | 成都诺恩生物科技有限公司 | A kind of suppress the polypeptide of new vessels, the medicine containing this polypeptide and application thereof |
| CN106459193A (en) * | 2014-04-17 | 2017-02-22 | 特瑞克隆艾迪福公司 | vNAR recombinant monoclonal antibodies that neutralize vascular endophelial growth factor VEGF |
-
2019
- 2019-01-11 CN CN201910030074.2A patent/CN109776656B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ515388A (en) * | 1999-05-14 | 2003-03-28 | Genesis Res & Dev Corp Ltd | Polynucleotides and polypeptides used to stimulate leukocyte growth and to modulate angiogenesis and treat neurological conditions |
| CN102365093A (en) * | 2009-03-30 | 2012-02-29 | 参天制药株式会社 | Prophylactic or therapeutic agent for retinal diseases and method for preventing or treating retinal diseases, each comprising jnk (c-jun n-terminal kinase)-inhibiting peptide, and use of the peptide |
| CN106459193A (en) * | 2014-04-17 | 2017-02-22 | 特瑞克隆艾迪福公司 | vNAR recombinant monoclonal antibodies that neutralize vascular endophelial growth factor VEGF |
| WO2016115732A1 (en) * | 2015-01-23 | 2016-07-28 | 上海市第一人民医院 | Polypeptide for inhibiting angiogenesis or growth and application thereof |
| CN105859833A (en) * | 2015-01-23 | 2016-08-17 | 上海市第人民医院 | Polypeptide for inhibition of blood vessel neogenesis or growth and application thereof |
| CN106220714A (en) * | 2016-09-26 | 2016-12-14 | 成都诺恩生物科技有限公司 | A kind of suppress the polypeptide of new vessels, the medicine containing this polypeptide and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| YUAN ZHANG等: "A novel peptide specifically binding to VEGF receptor suppresses angiogenesis in vitro and in vivo", 《SIGNAL TRANSDUCTION AND TARGETED THERAPY》 * |
| 宋玉林等: "新型两亲性肽诱导血管生成研究", 《生物医学工程学杂志》 * |
| 陈龙冠等: "针对HER-2的多肽疫苗CKL9与YL20的抗肿瘤活性研究", 《中国药理学通报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109776656B (en) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grisanti et al. | Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study | |
| US20070027102A1 (en) | Methods and compositions for treating macular degeneration | |
| Hou et al. | Controlled release of dexamethasone from an intravitreal delivery system using porous silicon dioxide | |
| Lai et al. | Triptolide-nanoliposome-APRPG, a novel sustained-release drug delivery system targeting vascular endothelial cells, enhances the inhibitory effects of triptolide on laser-induced choroidal neovascularization | |
| CN109593117A (en) | It is a kind of for the peptide C KA18N of angiogenesis inhibiting and its application | |
| CN101391098B (en) | Apitoxin liposome preparation and preparation method thereof | |
| TW201000135A (en) | Pharmaceutical composition for treating xerophthalmia and/or disorder of cornea/conjunctiva | |
| JP2023035974A (en) | Nano low molecular weight peptide fg and application thereof to preparation of drug for treatment and prevention of fundus vascular disease | |
| CN119499351A (en) | A polypeptide for angiogenesis and lymphangiogenesis-related diseases and its use | |
| WO2012079419A1 (en) | Pharmaceutical composition for treating macular degeneration | |
| CN109776656A (en) | It is a kind of for the peptide T IN7N of angiogenesis inhibiting and its application | |
| CN102166205A (en) | New medical application of paeonol and derivatives thereof | |
| CN101797223A (en) | Huperzine A preparations for eyes and application thereof | |
| CN112891326B (en) | A kind of alginic acid gel drug film loaded with natamycin and its preparation method | |
| CN111150831B (en) | Application of polypeptide KdPT | |
| CN104606666A (en) | Recombinant bovine alkaline fibroblast growth factor eye drops | |
| CN110339345B (en) | Recombinant human truncated keratinocyte growth factor-1 eye drops and preparation method and application thereof | |
| Wang et al. | A novel small PEPTIDE H-KI20 inhibits retinal neovascularization through the JNK/ATF2 signaling pathway | |
| CN113185595A (en) | Protein with activity of inhibiting growth of new blood vessels and inflammatory reaction and preparation method thereof | |
| CN107537036A (en) | A kind of pharmaceutical preparation of human vessel endothelium growth factor resisting monoclonal antibody and its application | |
| Zhang et al. | Tetrahedral Framework Nucleic Acid‐Based Delivery of DJ‐1‐saRNA Prevent Retinal Ischaemia–Reperfusion Injury via Inhibiting Ferroptosis | |
| TW202128746A (en) | Use of fusion protein for the treatment of age-related macular degeneration | |
| CN111346217B (en) | New application of polypeptide TDL23 | |
| CN114933635B (en) | Nano small peptide FH and application thereof in preparation of drugs for treating and preventing fundus vascular diseases | |
| CN118750522B (en) | Application of astaxanthin exosomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |